Wed, Aug 20, 2014, 11:50 PM EDT - U.S. Markets closed


% | $
Quotes you view appear here for quick access.

Insmed Incorporated Message Board

stu_har 4 posts  |  Last Activity: Aug 19, 2014 6:03 PM Member since: Feb 28, 2010
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to

    The Lancet Artical, August 16, 2014

    by g550drvr Aug 16, 2014 7:48 AM
    stu_har stu_har Aug 19, 2014 6:03 PM Flag

    g550 & fargo,
    Thank you, this is all good for AMRN.

  • Reply to

    The Lancet Artical, August 16, 2014

    by g550drvr Aug 16, 2014 7:48 AM
    stu_har stu_har Aug 16, 2014 11:13 AM Flag

    Nice find! Do you access to full article or just the summary? TIA.

  • Reply to


    by frenzychess Aug 8, 2014 8:38 AM
    stu_har stu_har Aug 8, 2014 8:59 AM Flag

    "John Jenkins, M.D., Director, Office of New Drugs
    Dr. Jenkins joined FDA as a medical officer in the Division of Oncology and Pulmonary Drug Products in 1992. He subsequently served as Pulmonary Medical Group Leader and Acting Division Director before being appointed as Director of the newly created Division of Pulmonary Drug Products in 1995. Dr. Jenkins became the Director of the Office of Drug Evaluation II in 1999 and served in that position until he was appointed to his current position in January 2002.

    Dr. Jenkins received his undergraduate degree in biology from East Tennessee State University in 1979 and his medical degree from the University of Tennessee at Memphis in 1983. He completed his postgraduate medical training in internal medicine, pulmonary disease, and critical care medicine at Virginia Commonwealth University/Medical College of Virginia from 1983 until 1988.

    Dr. Jenkins is Board Certified in internal medicine and pulmonary diseases by the American Board of Internal Medicine. Following completion of his medical training, Dr. Jenkins joined the faculty of MCV as an Assistant Professor of Pulmonary and Critical Care Medicine and as a Staff Physician at the McGuire VA Medical Center in Richmond."

    Hopefully the egos are able to be set aside and the CDER/FDA does what it is tasked with:
    To perform an essential public health task by making sure that safe and effective drugs are available to improve the health of people in the United States. We shall find out, GLTA.

  • Reply to

    Jenkins will consult with CEDAR on AMRN appeal

    by spook2b Aug 7, 2014 5:01 PM
    stu_har stu_har Aug 7, 2014 5:08 PM Flag

    CDER - Center for Drug Evaluation and Research.

13.45-0.28(-2.04%)Aug 20 4:00 PMEDT

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.